The struggling genetic-testing 23andMe is looking for a buyer for the virtual-care business it acquired in 2021, Business ...

Genetic testing firm 23andMe is reportedly considering the sale of its telehealth division, Lemonaid Health, according to ...

JMP Securities analyst Ronald Josey maintained Lemonade with a Market Outperform and raised the price target from $40 to $60.

Consumer DNA testing company 23andMe has signed a deal to acquire privately-held Lemonaid Health in a $400 million ... with the remainder in the form of stock. The transaction is expected to ...

Me (ME) has been quietly exploring a possible sale of its telehealth business, Lemonaid, according to Business Insider.Stay Ahead of the ...

The struggling health company bought virtual care startup Lemonaid in 2021 for $400 million. 23andMe's stock has plummeted after a 2023 data breach exposed millions of customer accounts.

The stock value of 23andMe has seen a significant drop following a data breach in 2023 that exposed numerous customer accounts. The potential sale of Lemonaid Health appears to be part of the ...

The struggling health company bought virtual care startup Lemonaid in 2021 for $400 million. 23andMe's stock has plummeted after a 2023 data breach exposed millions of customer accounts. Struggling ...